<DOC>
	<DOCNO>NCT01981759</DOCNO>
	<brief_summary>This study placebo-controlled 12 week trial DCS augmentation once-weekly CBT session 60 schizophrenia subject antipsychotic-resistant delusion . In addition test efficacy , trial characterize DCS effect term time course persistence response examine DCS effect memory consolidation cognitive flexibility possible mediator DCS enhancement CBT delusion .</brief_summary>
	<brief_title>D-Cycloserine Augmentation Cognitive Behavioral Therapy Delusions</brief_title>
	<detailed_description>This study consist placebo-controlled 12 week trial DCS augmentation once-weekly CBT session 60 schizophrenia subject antipsychotic-resistant delusion . In addition test efficacy , trial characterize DCS effect term time course persistence response examine DCS effect memory consolidation cognitive flexibility possible mediator DCS enhancement CBT delusion . This study conduct Schizophrenia Research Group NYU Langone Medical Center One Park Avenue 8th Floor Psychiatry Outpatient Clinic Bellevue Hospital locate New York , NY . Upon sign consent , patient undergo screen procedure assess eligibility . A diagnosis schizophrenia , schizoaffective disorder , delusional disorder determine Structured Clinical Interview DSM IV ( SCID ) complete research clinician use available clinical data confirm consensus diagnosis . A comprehensive medical history physical exam , include measurement vital sign , perform . A psychiatric history , include diagnosis , treatment history , current medication , substance use also perform . A research assistant complete demographic administer Scale Assessment Positive Symptoms-Delusions ( SAPS-D ) . At screening , fast blood sample obtain perform routine laboratory test include electrolyte , BUN , creatinine , liver function test , fast glucose , calcium , phosphate , magnesium , albumin CBC differential . Urinalysis perform identify unstable medical illness . A urine toxicology screen perform urine pregnancy test do woman child bear potential . Subjects meet study eligibility criterion complete Logical Memory Test portion Weschler Memory Scale-III ( WMS-III ) one week baseline visit . The baseline visit include follow assessment : SAPS-D , Psychotic Symptom Rating Scales ( PSYRATS ) , Brief Psychiatric Rating Scale ( BPRS ) , Scale Assessment Negative Symptoms ( SANS ) , Calgary Depression Rating Scale ( CDRS ) , Clinical Global Impression ( CGI ) , Heinrich 's Quality Life Scale ( Heinrich 's QOL ) , Peter 's Delusion Inventory ( PDI ) , Birchwood Insight Scale ( BIS ) , Drug Alcohol Questionnaire ( DAUQ ) , Pittsburg Sleep Quality Index ( PSQI ) . At baseline visit follow cognitive assessment administer : Logical Memory Test WMS-III , The Wisconsin Card Sort Test ( WCST ) , Verbal Fluency Test ( VFT ) , MATRICS Consensus Cognitive Battery ( MCCB ) . The clinical battery assessment include PSYRATS , BPRS , SANS , CDRS , CGI , Heinrich 's QOL perform week 4 , 8 , 12 , 24 , 36 . The delusion section PSYRATS perform week 2 , 3 , 6 , 10 . The Logical Memory Test administer screen visit 2 , baseline , week 3 , week 4 . The Alternative Beliefs Exercise occur week 3 , 4 , 12 . The WCST VFT give participant baseline visit week 12 . Side effect assess use Systematic Assessment Treatment Emergent Events ( SAFTEE ) week 3 , 4 , 8 , 12 . Beginning week 1 , participant engage hour long session Cognitive Behavioral Therapy delusion . This treatment course continue weekly week 1 week 12 ( 12 session ) . For first two session CBT week 1 2 , experimental placebo group receive 50 mg placebo pill mouth one hour CBT session . Starting week 2 , placebo experimental group receive respective drug one hour CBT session week 3-12 ( 50 mg placebo mouth placebo group , 50 mg D-cycloserine mouth experimental group ) . The primary outcome interest study change PSYRATS Delusions Subscale total score compare placebo baseline week 12 . Secondary outcome measure include change define 20 % reduction PSYRATS Delusions Subscale total score baseline 2 week DCS treatment versus placebo well change define maintenance 20 % great reduction PSYRATS Delusions Subscale total score baseline 3 6 month follow compare placebo .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Delusions</mesh_term>
	<mesh_term>Schizophrenia , Paranoid</mesh_term>
	<mesh_term>Cycloserine</mesh_term>
	<criteria>Age 1868 Diagnosis schizophrenia , schizoaffective disorder , delusional disorder Treated antipsychotic except clozapine least 8 week antipsychotic naive lifetime Willing participate CBT Sufficient proficiency English complete assessment Score least 3 SAPS two assessment , four week apart Current treatment clozapine SSRI treatment Active alcohol substance abuse within six week Unstable medical illness Pregnant nursing Anemia Renal insufficiency</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>68 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Delusions</keyword>
	<keyword>D-Cycloserine</keyword>
	<keyword>CBT</keyword>
</DOC>